Similar articles

• Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease.

  Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Abrams GA, et al. Hepatology. 2004 Aug;40(2):475-83. doi: 10.1002/hep.20323. Hepatology. 2004. PMID: 15368453
• Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver.

  Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Washington K, et al. Hum Pathol. 2000 Jul;31(7):822-8. doi: 10.1053/hupa.2000.8440. Hum Pathol. 2000. PMID: 10923919
• Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease.

  Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Martínez L, Chavez-Tapia NC, Baptista-González HA, Uribe M. Mendez-Sanchez N, et al. Liver Int. 2007 Mar;27(2):215-9. doi: 10.1111/j.1478-3231.2006.01401.x. Liver Int. 2007. PMID: 17311616
• Pathology of nonalcoholic fatty liver disease.

  Yeh MM, Brunt EM. Yeh MM, et al. Am J Clin Pathol. 2007 Nov;128(5):837-47. doi: 10.1309/RTPM1PY6YGBL2G2R. Am J Clin Pathol. 2007. PMID: 17951208 Review.
• Apoptosis and fibrosis in non-alcoholic fatty liver disease.

  Canbay A, Kip SN, Kahraman A, Gieseler RK, Nayci A, Gerken G. Canbay A, et al. Turk J Gastroenterol. 2005 Mar;16(1):1-6. Turk J Gastroenterol. 2005. PMID: 16252180 Review.